News

The Market Herald – Proteomics (ASX:PIQ) validates prognostic diabetes kidney test

Proteomics International Laboratories (PIQ) reports its PromarkerD predictive test for diabetic kidney disease has been validated in a major clinical study. The successful trial is another positive step towards Food and Drug Administration (FDA) approval in the U.S.

Article: Proteomics (ASX:PIQ) validates prognostic diabetes kidney test

Subscribe
  • This field is for validation purposes and should be left unchanged.